DeuterOncology
Description: DeuterOncology develops MET inhibitors for targeted lung cancer therapy, with a dual MET/RAS inhibitor in pre-clinical stages.
Country: Belgium
Based in: Geel
Founded: 2020
Funding Stage: Pre-Seed
Tags: ['Biotechnology', 'Medical', 'Drug Discovery']
ACCESS DIRECTORY
Details about how we process your information are available in our Privacy Policy.
